Pfizer Inc, Johnson & Johnson, AstraZeneca-Oxford University, Novavax and Moderna.Pfizer and its partner BioNTech could have late-stage clinical data as soon as the end of October, the vaccine makers had said earlier. "Based on current infection rates, the companies continue to expect that a conclusive readout on efficacy is likely by the end of October," Pfizer said earlier this month while seeking US regulator's approval to expand its trial to 44,000 participants.Data from Moderna is also expected soon after.